Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.9652W HIGH $3.16
Volume
334.17 K
Value Traded
1.26 M
Short % Float
4.64%
-1.53%Week
-9.47%1 Month
+7.05%3 Month
+128.32%6 Month
-89.89%5 Year
-89.89%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
58.69 M
EPS (TTM)
-2.81
P/E Ratio
-
Ent. Value
-13.94 M
Total Shares
22.75 M
Float Shares
17.50 M
Insiders
23.06%
Institutions
56.65%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BOLD Catalyst Timeline
Dated clinical, regulatory and corporate events for Boundless Bio, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Boundless Bio, Inc.
83Total events
5Upcoming
14Tier-1 (high impact)
2024 to 2026Coverage
Upcoming catalysts 2
Event history 50
▼Equity OfferingCorporate
Concurrent $230 million private placement co-led by RTW Investments and RA Capital Management
▲Partnership / LicenseSERP-01Corporate
Serapha licenses SERP-01 from YolTech Therapeutics for Greater China rights
Alpha-1 Antitrypsin Deficiencysource ↗
▲Trial InitiationSERP-01Trial
YolTech has been enrolling AATD patients in an IIT in Renji Hospital, Shanghai
Alpha-1 Antitrypsin Deficiencysource ↗
◆Enrollment UpdateBBI-940Trial
Enrollment ongoing in KOMODO-1 trial of BBI-940
ER+/HER2- breast cancer, TNBC-LARsource ↗
◆Poster PresentationBBI-940Presentation
Poster presentation at AACR 2026 on BBI-940 preclinical data
advanced or metastatic estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer or triple-negative breast cancer of the luminal androgen receptor subtype (TNBC-LAR)source ↗
◆Oral PresentationBBI-940Presentation
Preclinical data for BBI-940 presented at AACR 2026
ER+/HER2- breast cancer, TNBC-LARsource ↗
▲Trial InitiationBBI-940Trial
First-in-human Phase 1 KOMODO-1 trial initiated
advanced or metastatic ER+/HER2- breast cancer and TNBC-LARsource ↗
◆Runway Guidance UpdateCorporate
Cash position expected to fund operations into second half of 2026
▲Trial InitiationBBI-940Trial
KOMODO-1 trial open for enrollment
ER+/HER2- breast cancer; TNBC-LARsource ↗
◆Oral PresentationPresentation
Boundless Bio to participate in fireside chat at Guggenheim Emerging Outlook: Biotech Summit 2026
▼Trial DiscontinuedBBI-355DiscontinuedTrial
Ceased enrollment of POTENTIATE trial evaluating BBI-355 and BBI-825
oncogene-amplified cancerssource ↗
▼Trial DiscontinuedBBI-825DiscontinuedTrial
Ceased enrollment of POTENTIATE trial evaluating BBI-355 and BBI-825
oncogene-amplified cancerssource ↗
◆Trial InitiationBBI-940Trial
First-in-human clinical trial KOMODO-1 expected to initiate
metastatic breast cancersource ↗
▲Poster PresentationBBI-940Presentation
Preclinical data presented at AACR 2026 demonstrating anti-tumor activity and tumor regression in ecDNA+ models
ecDNA+ cancerssource ↗
▼Trial DiscontinuedBBI-355DiscontinuedTrial
Ceased enrollment in POTENTIATE trial for BBI-355 and BBI-825 combination
oncogene amplified cancerssource ↗
▼Trial DiscontinuedBBI-825DiscontinuedTrial
Ceased enrollment in POTENTIATE trial for BBI-355 and BBI-825 combination
oncogene amplified cancerssource ↗
◆Oral PresentationPresentation
Boundless Bio to participate in Piper Sandler 37th Annual Healthcare Conference fireside chat
◆Enrollment UpdateBBI-355DiscontinuedTrial
Enrollment ongoing in BBI-355/BBI-825 combination arm of POTENTIATE trial
oncogene amplified cancerssource ↗
◆Poster PresentationBBI-825DiscontinuedPresentation
Poster presentation on synergistic oral combination of BBI-825 with BBI-355 at AACR-NCI-EORTC 2025
oncogene amplified cancerssource ↗
◆Poster PresentationBBI-355DiscontinuedPresentation
Poster presentation on synergistic oral combination of BBI-825 with BBI-355 at AACR-NCI-EORTC 2025
oncogene amplified cancerssource ↗
▲Enrollment CompleteBBI-355DiscontinuedTrial
BBI-355/BBI-825 combination arm of POTENTIATE trial open for enrollment
oncogene amplified cancerssource ↗
●Development Candidate NominationBBI-940Preclinical
BBI-940 selected as development candidate for novel kinesin program
oncogene amplified cancerssource ↗
◆Oral PresentationPresentation
Boundless Bio to participate in fireside chat at Goldman Sachs 46th Annual Global Healthcare Conference
●Development Candidate NominationPreclinical
Development candidate nomination for third ecDTx program (ecDTx 3)
▼Program DiscontinuationBBI-355DiscontinuedCorporate
Discontinued monotherapy and combination arms of BBI-355 in POTENTIATE trial
oncogene amplified cancerssource ↗
▲Development Candidate NominationBBI-940Preclinical
Development candidate BBI-940 declared for novel Kinesin program
cancer (ecDNA amplified)source ↗
●Oral PresentationBBI-825DiscontinuedPresentation
Preclinical data for BBI-825 presented at AACR Annual Meeting
colorectal cancersource ↗
◆Oral PresentationPresentation
Boundless Bio presentation at Needham Virtual Healthcare Conference
◆Topline ReadoutBBI-355DiscontinuedClinical Data
Initial proof-of-concept data from BBI-355 Phase 1/2 POTENTIATE trial
oncogene-amplified cancerssource ↗
●Development Candidate NominationPreclinical
Development candidate nomination for Kinesin program
ecDNA amplified cancerssource ↗
◆Topline ReadoutBBI-825DiscontinuedClinical Data
Initial clinical proof-of-concept data expected
colorectal cancer with BRAFV600E or KRASG12C mutations and resistance gene amplificationssource ↗
Past FDA Catalysts and PDUFA Decisions
How BOLD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | BBI-940 (novel, orally bioavailable Kinesin degrader) | IND Submission | IND |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every BOLD program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| TANG KEVIN10% Owner | Sell | -18,300 2,840,635 held | $2.97 | 08/26/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BOLD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0.3 % | 6.40 M | 2.56 M |
BOLD Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BOLD ranks across every disease it competes in
Competitive Position is a premium feature
See how BOLD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBOLD News
BOLD▲ +85.7%on this news
Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement
Boundless Bio and Serapha Bio have announced a merger agreement, with Serapha Bio set to lead the combined company. The merger is supported by a $230 million private placement aimed at advancing Serapha's SERP-01 therapy for Alpha-1 Antitrypsin Deficiency. The transaction is expected to close in Q4 2026, pending stockholder approval and other conditions.
Read more →BOLD▼ -5.9%on this news
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights
Boundless Bio reported its financial results for Q1 2026, highlighting ongoing enrollment in the KOMODO-1 trial for BBI-940, a novel kinesin degrader. The company has a strong cash position of $93 million, expected to fund operations through mid-2028. Recent data presented at the AACR Annual Meeting supports BBI-940's therapeutic potential in treating ecDNA+ cancers. However, the company reported a net loss of $13.6 million for the quarter.
Read more →BOLDBoundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
Boundless Bio presented promising preclinical data for BBI-940, an oral kinesin degrader, at the 2026 AACR Annual Meeting. The data supports its use in treating advanced or metastatic breast cancers, particularly those with extrachromosomal DNA. The ongoing Phase 1 KOMODO-1 trial aims to evaluate its safety and efficacy in patients with specific breast cancer subtypes.
Read more →BOLDBoundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026
Boundless Bio has announced a poster presentation for its oral Kinesin degrader program at the AACR Annual Meeting 2026. The presentation will detail the development of BBI-940, a selective Kinesin degrader aimed at treating advanced breast cancer types. This innovative approach targets extrachromosomal DNA, which is linked to oncogene amplification in cancer cells. The presentation is scheduled for April 21, 2026, in San Diego.
Read more →BOLDBoundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Boundless Bio reported its financial results for Q4 and full year 2025, highlighting the open enrollment for the KOMODO-1 trial of BBI-940, a novel Kinesin degrader for breast cancer. The company has $108 million in cash, expected to fund operations into 2028, and anticipates initial proof-of-concept data from the trial. However, it will cease enrollment in the POTENTIATE trial due to market considerations.
Read more →BOLDBoundless Bio to Participate in the Leerink Global Healthcare Conference
Boundless Bio, a clinical-stage oncology company, announced its participation in the Leerink Global Healthcare Conference. CEO Zachary Hornby will engage in a fireside chat on March 11 in Miami, Florida. The company focuses on developing therapies targeting extrachromosomal DNA to address oncogene amplified cancers.
Read more →BOLDBoundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Boundless Bio will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, with CEO Zachary Hornby leading a fireside chat. The event is scheduled for February 12 in New York. Boundless Bio focuses on developing therapies targeting extrachromosomal DNA to treat oncogene amplified cancers, addressing significant unmet medical needs.
Read more →BOLDBoundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway
Boundless Bio has received FDA acceptance for its IND application for BBI-940, a novel Kinesin degrader aimed at treating metastatic breast cancer. The first-in-human trial, KOMODO-1, is set to begin in the first half of 2026. The company has also decided to discontinue the POTENTIATE trial to focus on programs with greater potential. Additionally, Boundless Bio's financial strategy extends its operational runway into 2028.
Read more →BOLDBoundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference
Boundless Bio will participate in the Piper Sandler 37th Annual Healthcare Conference, with CEO Zachary Hornby scheduled for a fireside chat on December 3. The company is focused on developing therapies targeting extrachromosomal DNA in cancer treatment. Their ongoing clinical trials include innovative compounds aimed at oncogene amplified tumors.
Read more →BOLDBoundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights
Boundless Bio reported its third quarter 2025 financial results, highlighting ongoing enrollment in the POTENTIATE trial for BBI-355 and BBI-825. The company is also preparing for a first-in-human trial of BBI-940, expected to start in the first half of 2026. With $118 million in cash, Boundless Bio anticipates funding its operations through 2028, aiming for significant clinical readouts.
Read more →BOLDBoundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Boundless Bio has announced a poster presentation at the 2025 AACR-NCI-EORTC International Conference. The presentation will showcase their research on the synergistic effects of BBI-825 and BBI-355 in targeting oncogene amplified cancers. This event highlights the company's commitment to addressing unmet needs in cancer therapeutics.
Read more →BOLDBoundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
Boundless Bio released its financial results and business highlights for Q2 2025, marking significant advancements in their oncology programs. The combination arm of the POTENTIATE trial for BBI-355 and BBI-825 is now open for enrollment, and the IND application for BBI-940 is on schedule for submission in early 2026. The company has a solid cash reserve of $127 million, expected to fund operations through early 2028. Executives express confidence in the scientific rationale behind their therapies aimed at oncogene-amplified cancers.
Read more →BOLDBoundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Boundless Bio will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, with CEO Zachary Hornby leading a fireside chat. The event is set for June 9 in Miami, FL, and will be accessible via a webcast. The company focuses on developing therapies targeting extrachromosomal DNA to treat oncogene amplified cancers.
Read more →BOLD▼ -15.6%on this news· ran to -29% by day 3
Boundless Bio Announces Portfolio Prioritization and Runway Extension
Boundless Bio has announced a strategic portfolio prioritization focusing on the combination therapy of BBI-355 and BBI-825, alongside the new candidate BBI-940. The company has extended its operational runway into the first half of 2028, allowing for anticipated proof-of-concept clinical readouts. However, it has discontinued certain clinical trials due to safety concerns.
Read more →BOLDBoundless Bio Reports First Quarter 2025 Financial Results and Business Highlights
Boundless Bio reported its first-quarter financial results for 2025, highlighting a robust cash position of $138 million, projected to support operations into 2027. The company is optimistic about the upcoming proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial, anticipated in late 2025, and the nomination of a development candidate for its Kinesin program by mid-2025. Despite a slight increase in net loss and administrative expenses compared to the prior year, Boundless remains committed to developing therapies for oncogene-amplified cancers.
Read more →BOLD▼ -7.4%on this news· ran to -26% by day 3
Boundless Bio to Participate in the Needham Virtual Healthcare Conference
Boundless Bio will participate in the Needham Virtual Healthcare Conference on April 10, 2025. CEO Zachary Hornby is scheduled to present, highlighting the company's focus on extrachromosomal DNA in cancer therapies. The session will be available live and archived on their website, showcasing their innovative approach in oncology.
Read more →BOLDBoundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
Boundless Bio has reported its fourth quarter and full year 2024 financial results, highlighting the ongoing Phase 1/2 POTENTIATE trial for BBI-355 in oncogene amplified cancers. The company anticipates releasing initial proof-of-concept data for this drug in the second half of 2025. Additionally, the development of a novel Kinesin program is underway, with candidate nomination expected by mid-2025. Boundless Bio ended 2024 with a robust cash position of $152 million, projected to fund operations through 2027.
Read more →BOLDBoundless Bio to Participate in the Leerink Global Healthcare Conference
Boundless Bio, a clinical-stage oncology company, announced its participation in the Leerink Global Healthcare Conference. CEO Zachary Hornby will engage in a fireside chat on March 12, 2025, in Miami, FL. The session will be available via live and archived webcast. Boundless Bio focuses on therapies targeting extrachromosomal DNA for oncogene amplified cancers.
Read more →BOLDBoundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer
Boundless Bio has appointed Dr. Robert Doebele as Chief Medical Officer, a strategic move as the company progresses its BBI-355 Phase 1/2 trial. Dr. Doebele brings a wealth of experience in precision oncology, having previously co-founded Rain Oncology and led significant clinical developments. His expertise is expected to enhance Boundless Bio's mission to create innovative therapies for patients with oncogene amplified cancers.
Read more →About Boundless Bio, Inc.
Headquarters11099 NORTH TORREY PINES ROAD, LA JOLLA, CA, 92037
BIOPHARMAWATCH ELITE PLUS
Trade the next BOLD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime